4 ms·
> CSDD’s finding, a bellwether figure in the drug industry, is based on an average out-of-pocket cost of $1.4 billion and an estimate of $1.2 billion in returns
by joewrong 9y ago
> CSDD’s finding, a bellwether figure in the drug industry, is based on an average out-of-pocket cost of $1.4 billion and an estimate of $1.2 billion in returns that investors forego on that money during the 10-plus years a drug candidate spends in development.
the estimate includes money that investors could have made if they invested elsewhere?
- aantix 9y agoOpportunity costs are real. Promising hypotheses are abundant and cheap. Exploring each with grueling, resource-intense, high-standard science is expensive. You have to make hard choices.